Xencor, Inc. (NASDAQ:XNCR – Get Free Report) has earned a consensus rating of “Moderate Buy” from the ten research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $24.8750.
Several research analysts have recently commented on XNCR shares. Royal Bank Of Canada increased their price target on shares of Xencor from $18.00 to $19.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Wedbush restated an “outperform” rating and set a $26.00 target price on shares of Xencor in a report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xencor in a research report on Monday, December 29th. JPMorgan Chase & Co. decreased their price target on Xencor from $20.00 to $18.00 and set an “overweight” rating for the company in a research note on Thursday, November 6th. Finally, Truist Financial initiated coverage on Xencor in a research note on Monday, November 24th. They issued a “buy” rating and a $29.00 price objective on the stock.
Check Out Our Latest Research Report on Xencor
Xencor Price Performance
Insider Buying and Selling
In other Xencor news, VP John R. Desjarlais sold 73,367 shares of the business’s stock in a transaction on Friday, December 19th. The shares were sold at an average price of $15.72, for a total transaction of $1,153,329.24. Following the completion of the transaction, the vice president owned 236,574 shares of the company’s stock, valued at $3,718,943.28. The trade was a 23.67% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bassil I. Dahiyat sold 114,377 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $15.71, for a total transaction of $1,796,862.67. Following the sale, the chief executive officer owned 466,635 shares of the company’s stock, valued at $7,330,835.85. This trade represents a 19.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 4.76% of the company’s stock.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the business. AQR Capital Management LLC bought a new stake in shares of Xencor in the first quarter valued at approximately $438,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Xencor by 9.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,047 shares of the biopharmaceutical company’s stock valued at $471,000 after purchasing an additional 3,692 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in Xencor by 89.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 726,734 shares of the biopharmaceutical company’s stock valued at $7,732,000 after purchasing an additional 344,088 shares during the period. Aberdeen Group plc boosted its holdings in Xencor by 48.2% in the 2nd quarter. Aberdeen Group plc now owns 558,810 shares of the biopharmaceutical company’s stock valued at $4,392,000 after purchasing an additional 181,698 shares during the period. Finally, Inspire Investing LLC grew its position in Xencor by 51.6% in the 2nd quarter. Inspire Investing LLC now owns 49,111 shares of the biopharmaceutical company’s stock worth $386,000 after purchasing an additional 16,709 shares during the last quarter.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.
The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.
Featured Articles
- Five stocks we like better than Xencor
- Nvidia CEO Issues Bold Tesla Call
- Your Bank Account Is No Longer Safe
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- The day the gold market broke
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.
